https://scholars.lib.ntu.edu.tw/handle/123456789/588130
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor.author | Zhu, Viola W | en_US |
dc.contributor.author | YEN-TING LIN | en_US |
dc.contributor.author | Kim, Dong-Wan | en_US |
dc.contributor.author | Loong, Herbert H | en_US |
dc.contributor.author | Nagasaka, Misako | en_US |
dc.contributor.author | To, Hao | en_US |
dc.contributor.author | Ang, Yvonne Li-En | en_US |
dc.contributor.author | Ock, Chan-Young | en_US |
dc.contributor.author | Tchekmedyian, Nishan | en_US |
dc.contributor.author | Ou, Sai-Hong Ignatius | en_US |
dc.contributor.author | Syn, Nicholas L | en_US |
dc.contributor.author | Reungwetwattana, Thanyanan | en_US |
dc.contributor.author | CHIA-CHI LIN | en_US |
dc.contributor.author | Soo, Ross A | en_US |
dc.date.accessioned | 2021-11-29T06:37:51Z | - |
dc.date.available | 2021-11-29T06:37:51Z | - |
dc.date.issued | 2020 | - |
dc.identifier.issn | 15560864 | - |
dc.identifier.uri | https://scholars.lib.ntu.edu.tw/handle/123456789/588130 | - |
dc.description.abstract | Lorlatinib, a next-generation central nervous system-penetrant ALK/ROS1 tyrosine kinase inhibitor (TKI), is approved to treat TKI-refractory ALK-positive (ALK+) NSCLC based on results from a phase 2 study. | en_US |
dc.language.iso | en | en_US |
dc.relation.ispartof | Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer | en_US |
dc.subject | ALK; Expanded access; Lorlatinib; NSCLC; ROS1; TKI-refractory | en_US |
dc.subject.classification | [SDGs]SDG3 | - |
dc.subject.other | alanine aminotransferase; anaplastic lymphoma kinase; ceritinib; crizotinib; lorlatinib; protein tyrosine kinase; protein tyrosine kinase inhibitor; receptor tyrosine kinase 1; unclassified drug; lorlatinib; macrocyclic lactam; oncoprotein; protein kinase inhibitor; protein tyrosine kinase; ROS1 protein, human; adult; aged; ALK gene; Article; blurred vision; body weight disorder; brain metastasis; carcinomatous meningitis; clinical trial; cognitive defect; cohort analysis; constipation; depression; dizziness; drug efficacy; drug response; drug safety; dry eye; edema; enzyme activity; fatigue; female; gait disorder; genetic analysis; hallucination; hemorrhoid; human; hypercholesterolemia; hypertransaminasemia; hypertriglyceridemia; major clinical study; male; median survival time; multicenter study; myalgia; non small cell lung cancer; peripheral neuropathy; pneumonia; priority journal; progression free survival; rash; ROS1 gene; side effect; treatment duration; tumor-related gene; genetics; Hong Kong; lung tumor; South Korea; Taiwan; Hong Kong; Humans; Lactams, Macrocyclic; Lung Neoplasms; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Proto-Oncogene Proteins; Receptor Protein-Tyrosine Kinases; Republic of Korea; Taiwan | - |
dc.title | An International Real-World Analysis of the Efficacy and Safety of Lorlatinib Through Early or Expanded Access Programs in Patients With Tyrosine Kinase Inhibitor–Refractory ALK-Positive or ROS1-Positive NSCLC | en_US |
dc.type | journal article | en |
dc.identifier.doi | 10.1016/j.jtho.2020.04.019 | - |
dc.identifier.pmid | 32360579 | - |
dc.identifier.scopus | 2-s2.0-85086020844 | - |
dc.identifier.url | https://scholars.lib.ntu.edu.tw/handle/123456789/493903 | - |
dc.relation.journalvolume | 15 | en_US |
dc.relation.journalissue | 9 | en_US |
dc.relation.pageend | 1496 | en_US |
item.languageiso639-1 | en | - |
item.cerifentitytype | Publications | - |
item.fulltext | no fulltext | - |
item.openairecristype | http://purl.org/coar/resource_type/c_6501 | - |
item.openairetype | journal article | - |
item.grantfulltext | none | - |
crisitem.author.dept | Medicine-NTUCC | - |
crisitem.author.dept | Internal Medicine | - |
crisitem.author.dept | Oncology-NTUH | - |
crisitem.author.orcid | 0000-0002-3350-9140 | - |
crisitem.author.parentorg | National Taiwan University Cancer Center (NTUCC) | - |
crisitem.author.parentorg | College of Medicine | - |
crisitem.author.parentorg | National Taiwan University Hospital | - |
顯示於: | 醫學系 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。